Dynamic contrast-enhanced MRI improves accuracy for detecting focal splenic involvement in children and adolescents with Hodgkin disease

Pediatric Radiology

Volumn 43, Issue 8, 2013, Pages 941-949

  Punwani, Shonit ^a,b   Cheung, King Kenneth ^a   Skipper, Nicholas ^a   Bell, Nichola ^b   Bainbridge, Alan ^a   Taylor, Stuart A ^a,b   Groves, Ashley M ^c   Hain, Sharon F ^c   Ben Haim, Simona ^c   Shankar, Ananth ^b   Daw, Stephen ^b   Halligan, Steve ^a,b   Humphries, Paul D ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Computed tomography; Hodgkin disease; Magnetic resonance imaging; Pediatrics; Positron emission tomography; Spleen

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISOLONE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE TECHNICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGIST; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SPLEEN DISEASE;

ADOLESCENT; ALGORITHMS; CHILD; CONTRAST MEDIA; FEMALE; HODGKIN DISEASE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; NEOPLASM STAGING; ORGANOMETALLIC COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPLENIC NEOPLASMS;

EID: 84880918801     PISSN: 03010449     EISSN: 14321998     Source Type: Journal    
DOI: 10.1007/s00247-012-2616-7     Document Type: Article

References (27)

1. Chavhan GB, Babyn PS (2011) Whole-body MR imaging in children: principles, technique, current applications, and future directions. Radiographics 31:1757-1772
2. Rueffer U, Sieber M, Stemberg M et al (2003) Spleen involvement in Hodgkin's lymphoma: assessment and risk profile. Ann Hematol 82:390-396
3. Pendlebury SC, Boyages S, Koutts J et al (1992) Thymic hyperplasia associated with Hodgkin disease and thyrotoxicosis. Cancer 70:1985-1987
4. Rathore B, Kadin ME (2010) Hodgkin's lymphoma therapy: past, present, and future. Expert Opin Pharmacother 11:2891-2906
5. Abdulqadhr G, Molin D, Astrom G et al (2011) Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol 52:173-180
6. Kwee TC, van Ufford HM, Beek FJ et al (2009) Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol 44:683-690
7. van Ufford HM, Kwee TC, Beek FJ et al (2011) Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. AJR Am J Roentgenol 196:662-669
8. Punwani S, Taylor SA, Bainbridge A et al (2010) Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging. Radiology 255:182-190
9. Mauch PM (1994) Controversies in the management of early stage Hodgkin's disease. Blood 83:318-329
10. Bhatia K, Sahdev A, Reznek RH (2007) Lymphoma of the spleen. Semin Ultrasound CT MR 28:12-20
11. Huang B, Law MW, Khong PL (2009) Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 251:166-174
12. Brenner D, Elliston C, Hall E et al (2001) Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 176:289-296
13. Kleinerman RA (2006) Cancer risks following diagnostic and therapeutic radiation exposure in children. Pediatr Radiol 36:121-125
14. Kleis M, Daldrup-Link H, Matthay K et al (2009) Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging 36:23-36
15. Mirowitz SA, Brown JJ, Lee JK et al (1991) Dynamic gadolinium-enhanced MR imaging of the spleen: normal enhancement patterns and evaluation of splenic lesions. Radiology 179:681-686
16. Landis JR, Koch GG (1977) An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 33:363-374
17. Bossuyt PM, Reitsma JB, Bruns DE et al (2003) Toward complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Acad Radiol 10:664-669
18. de Jong PA, van Ufford HM, Baarsiag HJ et al (2009) CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma. AJR Am J Roentgenol 192:745-753
19. Hoane BR, Shields AF, Porter BA et al (1994) Comparison of initial lymphoma staging using computed tomography (CT) and magnetic resonance (MR) imaging. Am J Hematol 47:100-105
20. Kellenberger CJ, Epelman M, Miller SF et al (2004) Fast STIR whole-body MR imaging in children. Radiographics 24:1317-1330
21. Runge VM, Williams NM (1998) Dynamic contrast-enhanced magnetic resonance imaging in a model of splenic metastasis. Invest Radiol 33:45-50
22. Chang WC, Liou CH, Kao HW et al (2007) Solitary lymphangioma of the spleen: dynamic MR findings with pathological correlation. Br J Radiol 80:e4-e6
23. Elsayes KM, Narra VR, Mukundan G et al (2005) MR imaging of the spleen: spectrum of abnormalities. Radiographics 25:967-982
24. Hernandez-Maraver D, Hernandez-Navarro F, Gomez-Leon N et al (2006) Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. Br J Haematol 135:293-302
25. Rini JN, Leonidas JC, Tomas MB et al (2003) 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 44:1072-1074
26. Rini JN, Manalili EY, Hoffman MA et al (2002) F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Clin Nucl Med 27:572-577
27. Lister TA, Crowther D, Sutcliffe SB et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636